The purpose of this study was to evaluate the efficacy and safety of poractant alfa (Curosurf®), administered by endotracheal (ET) instillation in hospitalized adult patients diagnosed with SARS-COV-19 acute respiratory distress syndrome (ARDS).
This was a multicentre, open-label, randomized phase II proof-of-concept study.
The efficacy and safety of poractant alfa was evaluated in terms of ventilatory free days
during the 21 days after randomization, in adult patients diagnosed with ARDS due to
SARS-COV-19 infection.
Each patient randomized to the study treatment received 3 administrations of Curosurf ® with
a 24 hours dosing interval. The assessment collection was up to Day 28, when the evaluation
occurred at the Intensive Care Unit (ICU), or by phone call if the patient has already been
discharged.
Seventy patients were planned to be randomized in the study with a ratio 3:2 (i.e. 42
patients in the poractant alfa arm and 28 in the control arm). The control arm population
received Standard of Care (SoC). This study was conducted in United Kingdom (UK), United
States of America (US), and Italy.
Overall, 13 patients (Curosurf ® group) and 8 patients (control group) were randomised in the
study. Due to low recruitment rate the study was terminated early for non-safety reasons.
Curosurf® is a pulmonary surfactant of natural origin which, when delivered endotracheally
(ET). Curosurf® is currently approved for marketing as treatment of premature neonates with
RDS or at risk of Respiratory Distress Syndrome (RDS). Chiesi Farmaceutici S.p.A (Chiesi)
conducted this study with its porcine-derived surfactant, Curosurf® (poractant alfa), to
evaluate the efficacy and safety in ventilated adult patients who were critically unwell in
intensive care with SARS-COV-19 ARDS.
Drug: CUROSURF® (poractant alfa)
Three administrations with a 24 hours dosing interval.
Each endotracheal (ET) administration 1, 2, and 3 consisted of poractant alfa bolus:
30mg /kg (Lean Body Weight-LBW) = 0.375ml /kg LBW, diluted with normal saline up to 2ml /kg LBW.
Inclusion Criteria:
Participants were eligible to be included in the study if the following criteria apply:
1. Male or female ≥18 and ≤ 80 years of age
2. Informed consent for participation in the study (refer to section 15 for detailed
inform consent procedure)
3. Positive 2019-nCoV Reverse Transcription Polymerase Chain Reaction (rt-PCR) before
randomisation
4. Arterial Partial Pressure of Oxygen/Fraction of Inspired Oxygen (PaO2/FiO2) ratio <
150 mmHg
5. Lung compliance ≤45 ml/cmH20
6. Intubated and artificially ventilated less than 48 hours before the first poractant
alfa administration
Exclusion Criteria:
Participants were excluded from the study if any of the following criteria apply:
1. Any contraindications to surfactant administration e.g., pulmonary hemorrhage and
pneumothorax)
2. Weight < 40kg
3. Stage 4 severe chronic kidney disease (i.e., Estimated Glomerular Filtration Rate
(eGFR) < 30)
4. Pregnancy
5. Administration of any nebulized surfactant in the 48 hours before the first poractant
alfa administration
6. Extracorporeal membrane oxygenation (ECMO)
Henry Ford Health System
Detroit, Michigan, United States
Chiesi site # 14
Bologna, Italy
Chiesi site #13
Modena, Italy
UCLH and UCL 250 Euston Road
London, United Kingdom
Chiesi site #4
London, United Kingdom
Chiesi site # 12
Southampton, United Kingdom
Clark Howard, Prof. /MD, Principal Investigator
University College, London